Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and SHR2554 in Relapsed or Refractory PTCL and NKTCL
NCT07615283Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and zeprumetostat in peripheral T-cell lymphoma (PTCL) and Natural killer T-cell lymphoma (NKTL), sponsored by Sun Yat-sen University. Primary endpoints: Dose Limiting Toxicities at 21 days, Recommended Phase II Dose at 4 months and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
adebrelimabzeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT07615283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615283.